NFE2L2 and type 2 diabetes mellitus: Indeed, a clinical trial for the treatment of patients with type 2 diabetes and chronic kidney disease with the triterpenoid Nrf2 activator bardoxolone methyl was interrupted prematurely because of an increased incidence of adverse cardiovascular events and death in drug recipients (16).